Research Progress and Clinical Application Prospects of Exosome-Related Genes in Bladder Cancer: A Review

Kai Li; Weidong Yang; Dongqing Wang

doi:10.23977/medsc.2026.070115

Research Progress and Clinical Application Prospects of Exosome-Related Genes in Bladder Cancer: A Review

Download as PDF

DOI: 10.23977/medsc.2026.070115 | Downloads: 2 | Views: 142

Author(s)

Kai Li ¹, Weidong Yang ¹, Dongqing Wang ¹

Affiliation(s)

¹ Department of Urology, Affiliated Hospital of Hebei University, Baoding, Hebei, China

Corresponding Author

Kai Li

ABSTRACT

Exosomes, as critical mediators of intercellular communication, carry genetic information that plays a pivotal role in the initiation, progression, metastasis, and therapeutic resistance of bladder cancer. This review systematically summarizes the expression profiles and functional mechanisms of exosome-related genes in bladder cancer, highlighting their emerging roles as biomarkers and therapeutic targets. By integrating recent advances from high-throughput sequencing, functional validation, and clinical translational studies, we explore the potential of exosome-derived coding and non-coding RNAs in the diagnosis, prognostic evaluation, and personalized treatment of bladder cancer. The review aims to provide new theoretical insights and strategic directions for precision medicine in bladder cancer, addressing current challenges and future opportunities in the field.

KEYWORDS

Exosomes; Exosome-related genes; Bladder cancer; Biomarkers; Tumor microenvironment; Liquid biopsy

CITE THIS PAPER

Kai Li, Weidong Yang, Dongqing Wang. Research Progress and Clinical Application Prospects of Exosome-Related Genes in Bladder Cancer: A Review. MEDS Clinical Medicine (2026). Vol. 7, No.1, 146-155. DOI: http://dx.doi.org/10.23977/medsc.2026.070115.

REFERENCES

[1] Zhou Q, Fang L, Tang Y, et al. Exosome-mediated delivery of artificial circular RNAs for gene therapy of bladder cancer. J Cancer. 2024;15(6):1770-1778. Published 2024. doi:10.7150/jca.90620 https://pubmed.ncbi.nlm.nih.gov/38370378/
[2] Song Q, Yu H, Cheng Y, et al. Bladder cancer-derived exosomal KRT6B promotes invasion and metastasis by inducing EMT and regulating the immune microenvironment. J Transl Med. 2022;20(1):308. Published 2022 Jul 6. doi:10.1186/s12967-022-03508-2 https://pubmed.ncbi.nlm.nih.gov/35794606/
[3] Ghasroldasht MM, Agarwal PK. The role of exosomes in bladder cancer immunotherapy. J Natl Cancer Cent. 2025;5(3):252-266. Published 2025 Jun. doi:10.1016/j.jncc.2025.04.001 https://pubmed.ncbi.nlm.nih.gov/40693234/
[4] Yang Y, Miao L, Lu Y, Sun Y, Wang S. Exosome, the glass slipper for Cinderella of cancer-bladder cancer? J Nanobiotechnology. 2023;21(1):368. Published 2023 Oct 7. doi:10.1186/s12951-023-02130-8 https://pubmed.ncbi.nlm.nih.gov/37805491/
[5] Huang K, Yang C, Xu Y, Wang Y. Unraveling the multifaceted roles of extracellular vesicles in bladder cancer: diagnostic insights and therapeutic opportunities. Front Oncol. 15:1554819. Published 2025. doi:10.3389/fonc.2025.1554819 https://pubmed.ncbi.nlm.nih.gov/40395335/
[6] Shen Y, Ye H, Zhang D, et al. The role of exosomal CDC6 in the hirudin-mediated suppression of the malignant phenotype of bladder cancer cells. Gene. 821:146269. doi:10.1016/j.gene.2022.146269 https://pubmed.ncbi.nlm.nih.gov/35150820/
[7] Tang H, Liu X, Ke J, et al. New perspectives of exosomes in urologic malignancies - Mainly focus on biomarkers and tumor microenvironment. Pathol Res Pract. 263:155645. doi:10.1016/j.prp.2024.155645 https://pubmed.ncbi.nlm.nih.gov/39476607/
[8] Wang X, Song D, Zhu B, Jin Y, Cai C, Wang Z. Urinary exosomal mRNA as a biomarker for the diagnosis of bladder cancer. Anticancer Drugs. 2024;35(4):362-370. doi:10.1097/CAD.0000000000001571 https://pubmed.ncbi.nlm.nih.gov/38385960/
[9] Yuan H, Wang T, Peng P, et al. Urinary Exosomal miR-17-5p Accelerates Bladder Cancer Invasion by Repressing its Target Gene ARID4B and Regulating the Immune Microenvironment. Clin Genitourin Cancer. 2024;22(2):569-579.e1. doi:10.1016/j.clgc.2024.01.012 https://pubmed.ncbi.nlm.nih.gov/38383173/
[10] Krishnan S, Kanthaje S, Rekha PD, Mujeeburahiman M, Ratnacaram CK. Expanding frontiers in liquid biopsy-discovery and validation of circulating biomarkers in renal cell carcinoma and bladder cancer. Int Rev Cell Mol Biol. 391:135-197. doi:10.1016/bs.ircmb.2024.08.005 https://pubmed.ncbi.nlm.nih.gov/39939075/
[11] Yuan F, Yin XY, Huang Y, et al. Exosomal miR-93-5p as an important driver of bladder cancer progression. Transl Androl Urol. 2023;12(2):286-299. doi:10.21037/tau-22-872 https://pubmed.ncbi.nlm.nih.gov/36915886/
[12] Liu SC, Cao YH, Chen LB, Kang R, Huang ZX, Lu XS. BMSC-derived exosomal lncRNA PTENP1 suppresses the malignant phenotypes of bladder cancer by upregulating SCARA5 expression. Cancer Biol Ther. 2022;23(1):1-13. doi:10.1080/15384047.2022.2102360 https://pubmed.ncbi.nlm.nih.gov/35998226/
[13] Liu C, Xu P, Shao S, et al. The value of urinary exosomal lncRNA SNHG16 as a diagnostic biomarker for bladder cancer. Mol Biol Rep. 2023;50(10):8297-8304. doi:10.1007/s11033-023-08667-z https://pubmed.ncbi.nlm.nih.gov/37592177/
[14] Zheng H, Chen C, Luo Y, et al. Tumor-derived exosomal BCYRN1 activates WNT5A/VEGF-C/VEGFR3 feedforward loop to drive lymphatic metastasis of bladder cancer. Clin Transl Med. 2021;11(7):e497. doi:10.1002/ctm2.497 https://pubmed.ncbi.nlm.nih.gov/34323412/
[15] Rezaeian A, Khatami F, Heidari Keshel S, et al. The effect of mesenchymal stem cells-derived exosomes on the prostate, bladder, and renal cancer cell lines. Sci Rep. 2022;12(1):20924. Published 2022 Dec 3. doi:10.1038/s41598-022-23204-x https://pubmed.ncbi.nlm.nih.gov/36463254/
[16] Guo Y, Li Z, Sun W, et al. M2 Tumor Associate Macrophage- (TAM-) Derived lncRNA HISLA Promotes EMT Potential in Bladder Cancer. J Oncol. 2022:8268719. Published 2022. doi:10.1155/2022/8268719 https://pubmed.ncbi.nlm.nih.gov/39280890/
[17] Huyan T, Gao L, Gao N, et al. miR-221-5p and miR-186-5p Are the Critical Bladder Cancer Derived Exosomal miRNAs in Natural Killer Cell Dysfunction. Int J Mol Sci. 2022;23(23). Published 2022 Dec 2. doi:10.3390/ijms232315177 https://pubmed.ncbi.nlm.nih.gov/36499501/
[18] Liu Z, Du D, Zhang S. Tumor-derived exosomal miR-1247-3p promotes angiogenesis in bladder cancer by targeting FOXO1. Cancer Biol Ther. 2024;25(1):2290033. doi:10.1080/15384047.2023.2290033 https://pubmed.ncbi.nlm.nih.gov/38073044/
[19] Zhou Q, Ding W, Qian Z, et al. Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived Mimetic Nanovesicles to Treat Bladder Cancer. Mol Pharm. 2021;18(11):4015-4028. doi:10.1021/acs.molpharmaceut.1c00448 https://pubmed.ncbi.nlm.nih.gov/34648293/
[20] Lin H, Shi X, Li H, et al. Urinary Exosomal miRNAs as biomarkers of bladder Cancer and experimental verification of mechanism of miR-93-5p in bladder Cancer. BMC Cancer. 2021;21(1):1293. Published 2021 Dec 3. doi:10.1186/s12885-021-08926-x https://pubmed.ncbi.nlm.nih.gov/34861847/
[21] Su Q, Wu H, Zhang Z, Lu C, Zhang L, Zuo L. Exosome-Derived Long Non-Coding RNAs as Non-Invasive Biomarkers of Bladder Cancer. Front Oncol. 11:719863. Published 2021. doi:10.3389/fonc.2021.719863 https://pubmed.ncbi.nlm.nih.gov/34490118/
[22] Yang C, Wu S, Mou Z, et al. Exosome-derived circTRPS1 promotes malignant phenotype and CD8+ T cell exhaustion in bladder cancer microenvironments. Mol Ther. 2022;30(3):1054-1070. doi:10.1016/j.ymthe.2022.01.022 https://pubmed.ncbi.nlm.nih.gov/35038580/
[23] Cao C, Wang Y, Deng X, et al. Exosomes containing miR-152-3p targeting FGFR3 mediate SLC7A7-induced angiogenesis in bladder cancer. NPJ Precis Oncol. 2025;9(1):71. Published 2025 Mar 12. doi:10.1038/s41698-025-00859-z https://pubmed.ncbi.nlm.nih.gov/40075158/
[24] Zhou X, Kurywchak P, Wolf-Dennen K, et al. Unique somatic variants in DNA from urine exosomes of individuals with bladder cancer. Mol Ther Methods Clin Dev. 22:360-376. Published 2021 Sep 10. doi:10.1016/j.omtm.2021.05.010 https://pubmed.ncbi.nlm.nih.gov/34514028/
[25] Zhu Q, Cheng L, Deng C, et al. The genetic source tracking of human urinary exosomes. Proc Natl Acad Sci U S A. 2021;118(43). doi:10.1073/pnas.2108876118 https://pubmed.ncbi.nlm.nih.gov/34663731/
[26] Shen H, Zheng F, Tang X, et al. Constructing a bladder cancer prognostic model related to exosome using machine learning and identifying THBS1 as a potential target. Cancer Cell Int. 2025;25(1):392. Published 2025 Nov 7. doi:10.1186/s12935-025-04027-y https://pubmed.ncbi.nlm.nih.gov/41204322/
[27] Guo Y, Sun W, Gao W, et al. Long Noncoding RNA H19 Derived from M2 Tumor-Associated Macrophages Promotes Bladder Cell Autophagy via Stabilizing ULK1. J Oncol. 2022:3465459. Published 2022. doi:10.1155/2022/3465459 https://pubmed.ncbi.nlm.nih.gov/35607322/
[28] Cheng K, Li W, Wu H, Li C. Mapping knowledge structure and themes trends of cancer-associated fibroblasts: a text-mining study. Front Mol Biosci. 10:1302016. Published 2023. doi:10.3389/fmolb.2023.1302016 https://pubmed.ncbi.nlm.nih.gov/38111465/
[29] Zhan Y, Zhou Z, Zhu Z, et al. Exosome-transmitted LUCAT1 promotes stemness transformation and chemoresistance in bladder cancer by binding to IGF2BP2. J Exp Clin Cancer Res. 2025;44(1):80. Published 2025 Mar 3. doi:10.1186/s13046-025-03330-w https://pubmed.ncbi.nlm.nih.gov/40025525/
[30] Pan G, Jiang B, Yi Z, Yin J, Liu Y. Exosomal miR-105-5p derived from bladder cancer stem cells targets for GPR12 to promote the malignancy of bladder cancer. BMC Urol. 2023;23(1):155. Published 2023 Oct 3. doi:10.1186/s12894-023-01326-2 https://pubmed.ncbi.nlm.nih.gov/37789353/
[31] Bitiņa-Barlote Ē, Plonis J, Andrejeva M, et al. Profiles of urinal exosomal miRNAs derived from bladder cancer. Cent European J Urol. 2024;77(3):361-374. doi:10.5173/ceju.2023.279.R1 https://pubmed.ncbi.nlm.nih.gov/40115475/
[32] Liu M, Jia G, Meng X, et al. Cyclic Enrichment of Urinary Exosomes Using a MOF-on-MOF-Based Asymmetric Impinging Streams Chip for Bladder Cancer Diagnosis and Prognosis Prediction. Adv Healthc Mater. 2025;14(14):e2500848. doi:10.1002/adhm.202500848 https://pubmed.ncbi.nlm.nih.gov/40296360/
[33] Parker Kerrigan BC, Ledbetter D, Kronowitz M, et al. RNAi technology targeting the FGFR3-TACC3 fusion breakpoint: an opportunity for precision medicine. Neurooncol Adv. 2020 Jan-Dec;2(1):vdaa132. Published 2020 Jan-Dec. doi:10.1093/noajnl/vdaa132 https://pubmed.ncbi.nlm.nih.gov/33241214/
[34] Cai X, Qu L, Yang J, et al. Exosome-transmitted microRNA-133b inhibited bladder cancer proliferation by upregulating dual-specificity protein phosphatase 1. Cancer Med. 2020;9(16):6009-6019. doi:10.1002/cam4.3263 https://pubmed.ncbi.nlm.nih.gov/32627968/
[35] Bitiņa-Barlote Ē, Bļizņuks D, Siliņa S, et al. Liquid Biopsy Based Bladder Cancer Diagnostic by Machine Learning. Diagnostics (Basel). 2025;15(4). Published 2025 Feb 18. doi:10.3390/diagnostics15040492 https://pubmed.ncbi.nlm.nih.gov/40002643/
[36] Li H, Huang P, Wang Y, Zhang M, Gao D. Exosomal gene signature in esophageal carcinoma: Insights from single-cell and bulk RNA sequencing. Transl Oncol. 61:102490. doi:10.1016/j.tranon.2025.102490 https://pubmed.ncbi.nlm.nih.gov/40816225/

Subscription

E-Mail Alert

Downloads:	10955
Visits:	875747

Research Progress and Clinical Application Prospects of Exosome-Related Genes in Bladder Cancer: A Review

Author(s)

Affiliation(s)

Corresponding Author

ABSTRACT

KEYWORDS

CITE THIS PAPER

REFERENCES

RESOURCES

JOIN US

PUBLICATION SERVICES

CONTACT US